Philippe Corcia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3173823/publications.pdf

Version: 2024-02-01

142 papers	5,820 citations	81900 39 h-index	91884 69 g-index
161 all docs	161 docs citations	161 times ranked	8060 citing authors

#	Article	IF	Citations
1	The hypometabolic state: a good predictor of a better prognosis in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 41-47.	1.9	11
2	Reply to the letter from Gazulla. European Journal of Neurology, 2022, 29, e3-e4.	3.3	0
3	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
4	VEXAS syndrome extends the neurological complications of haemopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 685-685.	1.9	1
5	Neurolysis of the distal segment of the long thoracic nerve for the treatment of scapular winging due to serratus anterior palsy: a continuous series of 73 cases. Journal of Shoulder and Elbow Surgery, 2022, 31, 2140-2146.	2.6	2
6	Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis. Biomedicines, 2022, 10, 1307.	3.2	7
7	The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy. Neurology, 2021, 96, 214-225.	1.1	11
8	The Effect of <scp>SMN</scp> Gene Dosage on <scp>ALS</scp> Risk and Disease Severity. Annals of Neurology, 2021, 89, 686-697.	5.3	10
9	Effect of familial clustering in the genetic screening of 235 French ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 479-484.	1.9	7
10	Dysregulations of Expression of Genes of the Ubiquitin/SUMO Pathways in an In Vitro Model of Amyotrophic Lateral Sclerosis Combining Oxidative Stress and SOD1 Gene Mutation. International Journal of Molecular Sciences, 2021, 22, 1796.	4.1	10
11	Impact of a frequent nearsplice SOD1 variant in amyotrophic lateral sclerosis: optimising SOD1 genetic screening for gene therapy opportunities. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 942-949.	1.9	7
12	Therapeutic news in ALS. Revue Neurologique, 2021, 177, 544-549.	1.5	22
13	The future of ALS might move towards Genetic Therapy. Revue Neurologique, 2021, 177, 613-614.	1.5	1
14	Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: Supplementary evidence for a continuum. European Journal of Neurology, 2021, 28, 2780-2783.	3.3	9
15	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1126-1130.	1.9	25
16	Frontotemporal Pathology in Motor Neuron Disease Phenotypes: Insights From Neuroimaging. Frontiers in Neurology, 2021, 12, 723450.	2.4	16
17	Is There a Role for Vitamin D in Amyotrophic Lateral Sclerosis? A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2020, 11, 697.	2.4	8
18	Pre-symptomatic diagnosis in ALS. Revue Neurologique, 2020, 176, 166-169.	1.5	8

#	Article	IF	Citations
19	Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 2020, 21, 1103-1110.	1.8	14
20	A novel mutation in the cleavage site N291 of TDP-43 protein in a familial case of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 463-466.	1.7	1
21	Genetics of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 28-34.	1.7	13
22	ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	3.3	33
23	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	1.9	118
24	Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 2384-2394.	3.7	49
25	Typical bulbar ALS can be linked to GARS mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 275-277.	1.7	7
26	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.1	105
27	The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?. Brain, 2019, 142, 1176-1194.	7.6	128
28	Ferritin and LDL-cholesterol as biomarkers of fat-free mass loss in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 441-444.	1.7	4
29	A ferroptosisâ€“based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Scientific Reports, 2019, 9, 2918.	3.3	91
30	Staging amyotrophic lateral sclerosis: A new focus on progression. Revue Neurologique, 2019, 175, 277-282.	1.5	12
31	Development of permanent brain damage after subacute encephalopathy with seizures in alcoholics. Journal of the Neurological Sciences, 2019, 396, 12-17.	0.6	4
32	Phenotypic and genotypic studies of ALS cases in ALS-SMA families. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 432-437.	1.7	8
33	Age-dependent neurodegeneration and organelle transport deficiencies in mutant TDP43 patient-derived neurons are independent of TDP43 aggregation. Neurobiology of Disease, 2018, 115, 167-181.	4.4	67
34	The Metabolic Disturbances of Motoneurons Exposed to Glutamate. Molecular Neurobiology, 2018, 55, 7669-7676.	4.0	12
35	Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration. Molecular Neurobiology, 2018, 55, 6480-6499.	4.0	59
36	Nerve Biopsy Is Still Useful in Some Inherited Neuropathies. Journal of Neuropathology and Experimental Neurology, 2018, 77, 88-99.	1.7	16

#	Article	IF	Citations
37	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
38	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
39	Liver X Receptor Genes Variants Modulate ALS Phenotype. Molecular Neurobiology, 2018, 55, 1959-1965.	4.0	28
40	Mutation in the RRM2 domain of TDP-43 in Amyotrophic Lateral Sclerosis with rapid progression associated with ubiquitin positive aggregates in cultured motor neurons. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 149-151.	1.7	11
41	The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument?. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 273-279.	2.8	27
42	C-reactive protein: A promising biomarker in ALS?. Revue Neurologique, 2018, 174, 104-105.	1.5	2
43	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.7	22
44	In ALS, a mutation could be worth two steps. Revue Neurologique, 2018, 174, 669-670.	1.5	5
45	Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 500-505.	1.7	5
46	How Can a Ketogenic Diet Improve Motor Function?. Frontiers in Molecular Neuroscience, 2018, 11, 15.	2.9	49
47	A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. PLoS ONE, 2018, 13, e0198116.	2.5	64
48	A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 298-301.	1.7	21
49	Wildtype motoneurons, ALSâ€Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia, 2017, 65, 592-605.	4.9	62
50	A decrease in blood cholesterol after gastrostomy could impact survival in ALS. European Journal of Clinical Nutrition, 2017, 71, 1133-1135.	2.9	11
51	Genetics of amyotrophic lateral sclerosis. Revue Neurologique, 2017, 173, 254-262.	1.5	52
52	ALS and frontotemporal dementia belong to a common disease spectrum. Revue Neurologique, 2017, 173, 273-279.	1.5	56
53	<scp>SOD</scp>1 mutation can mask C9<scp>orf</scp>72 abnormal expansion. European Journal of Neurology, 2017, 24, e24.	3.3	2
54	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41

#	Article	IF	Citations
55	Inhibition of Î²-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis. Scientific Reports, 2017, 7, 5235.	3.3	53
56	Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. Journal of the Neurological Sciences, 2017, 380, 124-127.	0.6	27
57	Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 519-527.	1.7	17
58	Are the clinical classifications for psychogenic nonepileptic seizures reliable?. Epilepsy and Behavior, 2017, 77, 53-57.	1.7	15
59	Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline Metabolism. Molecular Neurobiology, 2017, 54, 5361-5374.	4.0	40
60	Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. Canadian Journal of Neurological Sciences, 2017, 44, 90-95.	0.5	105
61	Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 263-276.	2.8	29
62	Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Scientific Reports, 2017, 7, 17652.	3.3	110
63	An UPLC-MSMS method to measure plasma homocysteine concentration. Annales De Biologie Clinique, 2017, 75, 334-338.	0.1	1
64	Current view and perspectives in amyotrophic lateral sclerosis. Neural Regeneration Research, 2017, 12, 181.	3.0	26
65	Simultaneous Combined Myositis, Inflammatory Polyneuropathy, and Overlap Myasthenic Syndrome. Case Reports in Neurological Medicine, 2016, 2016, 1-11.	0.4	1
66	NSC-34 Motor Neuron-Like Cells Are Unsuitable as Experimental Model for Glutamate-Mediated Excitotoxicity. Frontiers in Cellular Neuroscience, 2016, 10, 118.	3.7	41
67	Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. European Journal of Neurology, 2016, 23, 346-353.	3.3	31
68	Metabolomics in amyotrophic lateral sclerosis: how far can it take us?. European Journal of Neurology, 2016, 23, 447-454.	3.3	36
69	Inborn Errors of Metabolism in Elderly Adults. Journal of the American Geriatrics Society, 2016, 64, e57-8.	2.6	2
70	Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours. Epilepsy and Behavior, 2016, 61, 237-241.	1.7	33
71	Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism. Neurotherapeutics, 2016, 13, 905-917.	4.4	46
72	Pseudo spastic gait can reveal a Stiff Leg Syndrome (SLS). Clinical Neurology and Neurosurgery, 2016, 147, 108-109.	1.4	2

#	Article	IF	Citations
73	Pure cerebellar ataxia linked to large C9orf72 repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 301-303.	1.7	15
74	Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis. Human Molecular Genetics, 2016, 25, ddw304.	2.9	15
75	Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies. Expert Review of Neurotherapeutics, 2016, 16, 1111-1119.	2.8	10
76	Further development of biomarkers in amyotrophic lateral sclerosis. Expert Review of Molecular Diagnostics, 2016, 16, 853-868.	3.1	17
77	Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy, 2016, 17, 1669-1682.	1.8	14
78	Inhibition of Pathogenic Mutant SOD1 Aggregation in Cultured Motor Neuronal Cells by Prevention of Its SUMOylation on Lysine 75. Neurodegenerative Diseases, 2016, 16, 161-171.	1.4	13
79	Epidemiology of amyotrophic lateral sclerosis: A review of literature. Revue Neurologique, 2016, 172, 37-45.	1.5	90
80	Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2016, 53, 6910-6924.	4.0	37
81	Functional Outcome of Hemorrhagic Transformation after Thrombolysis for Ischemic Stroke: A Prospective Study. Cerebrovascular Diseases Extra, 2015, 5, 103-106.	1.5	10
82	Vitamin D is Not a Protective Factor in <scp>ALS</scp>. CNS Neuroscience and Therapeutics, 2015, 21, 651-656.	3.9	32
83	Nutritional assessment of amyotrophic lateral sclerosis in routine practice: Value of weighing and bioelectrical impedance analysis. Muscle and Nerve, 2015, 51, 479-484.	2.2	32
84	Biological followâ€up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. European Journal of Neurology, 2015, 22, 1385-1390.	3.3	30
85	Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis. PLoS ONE, 2015, 10, e0131512.	2.5	40
86	Brait-Fahn-Schwarz disease: The missing link between ALS and Parkinson's disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 135-136.	1.7	5
87	Amyotrophic Lateral Sclerosis and Dementia. , 2015, , 23-34.		1
88	Is there a paraneoplastic ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 252-257.	1.7	28
89	A common functional allele of the Nogo receptor gene, reticulon 4 receptor (RTN4R), is associated with sporadic amyotrophic lateral sclerosis in a French population. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 490-496.	1.7	6
90	Comparative analysis of targeted metabolomics: Dominance-based rough set approach versus orthogonal partial least square-discriminant analysis. Journal of Biomedical Informatics, 2015, 53, 291-299.	4.3	73

#	Article	IF	Citations
91	Value of Nerve Biopsy in Patients With Latent Malignant Hemopathy and Peripheral Neuropathy. Medicine (United States), 2015, 94, e394.	1.0	20
92	A novel p.E121G SOD1 mutation in slowly progressive form of amyotrophic lateral sclerosis induces cytoplasmic aggregates in cultured motor neurons and reduces cell viability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 131-134.	1.7	6
93	Iron Metabolism Disturbance in a French Cohort of ALS Patients. BioMed Research International, 2014, 2014, 1-6.	1.9	52
94	The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development. Current Medicinal Chemistry, 2014, 21, 3551-3575.	2.4	132
95	Neuroinflammation and ï¿½ Amyloid Deposition in Alzheimer's Disease: In vivo Quantification with Molecular Imaging. Dementia and Geriatric Cognitive Disorders, 2014, 37, 1-18.	1.5	21
96	Somatosensory Evoked Potentials in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of Clinical Neurophysiology, 2014, 31, 241-245.	1.7	11
97	Isolated paralysis of the serratus anterior muscle: Surgical release of the distal segment of the long thoracic nerve in 52 patients. Orthopaedics and Traumatology: Surgery and Research, 2014, 100, S243-S248.	2.0	28
98	Advances in Cellular Models to Explore the Pathophysiology of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2014, 49, 966-983.	4.0	19
99	Development of monoclonal antibodies to human kallikrein-related peptidase 6 (KLK6) and their use in an immunofluorometric assay for free KLK6. Biological Chemistry, 2014, 395, 1119-1126.	2.5	1
100	Untargeted ¹ H-NMR metabolomics in CSF. Neurology, 2014, 82, 1167-1174.	1.1	42
101	Quelle place pour lâ€™enquÃªte familiale dans la sclÃ©rose latÃ©rale amyotrophiqueÂ?. Pratique Neurologique - FMC, 2014, 5, 95-98.	0.1	0
102	Cubital tunnel syndrome: Comparative results of a multicenter study of 4 surgical techniques with a mean follow-up of 92months. Orthopaedics and Traumatology: Surgery and Research, 2014, 100, S205-S208.	2.0	70
103	Syndrome tunnel cubitalÂâ€“ÃÃ‰tude comparative multicentrique de 4Âtechniques chirurgicales avec 92mois de recul. Revue De Chirurgie Orthopedique Et Traumatologique, 2014, 100, S1-S5.	0.0	0
104	Peripheral Myelin Protein 22 gene duplication with atypical presentations: A new example of the wide spectrum of Charcot-Marie-Tooth 1A disease. Neuromuscular Disorders, 2014, 24, 524-528.	0.6	18
105	A novel SOD1 mutation p.V31A identified with a slowly progressive form of amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 266.e1-266.e4.	3.1	17
106	New therapy options for amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy, 2013, 14, 1907-1917.	1.8	19
107	Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry. Journal of Proteome Research, 2013, 12, 3746-3754.	3.7	77
108	Distribution physiologique cÃ©rÃ©brale et corps entier du 18F-DPA-714Âen TEP/TDM. Medecine Nucleaire, 2013, 37, 44-51.	0.2	0

#	Article	IF	Citations
109	Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis. International Journal of Neuroscience, 2013, 123, 366-374.	1.6	29
110	Benign lower limb amyotrophy due to TARDBP mutation or post-polio syndrome?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 476-478.	1.7	8
111	Genome-wide significant association ofANKRD55rs6859219 and multiple sclerosis risk. Journal of Medical Genetics, 2013, 50, 140-143.	3.2	34
112	Biological and neuroimaging biomarkers for amyotrophic lateral sclerosis: 2013 and beyond. Neurodegenerative Disease Management, 2013, 3, 427-444.	2.2	1
113	A Rare Motor Neuron Deleterious Missense Mutation in theDPYSL3(CRMP4) Gene is Associated with ALS. Human Mutation, 2013, 34, 953-960.	2.5	30
114	Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology, 2012, 78, 1519-1526.	1.1	72
115	Phenotype difference between ALS patients with expanded repeats inC9ORF72and patients with mutations in other ALS-related genes. Journal of Medical Genetics, 2012, 49, 258-263.	3.2	157
116	Closing the case ofAPOEin multiple sclerosis: no association with disease risk in over 29â€…000 subjects: Figure 1. Journal of Medical Genetics, 2012, 49, 558-562.	3.2	31
117	Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nuclear Medicine and Biology, 2012, 39, 570-578.	0.6	115
118	Amyotrophic lateral sclerosis: A hormonal condition?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 585-588.	2.1	57
119	Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. European Journal of Human Genetics, 2012, 20, 588-591.	2.8	21
120	Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e52941.	2.5	203
121	Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Therapeutics and Clinical Risk Management, 2012, 8, 359.	2.0	16
122	Elevated Serum Ferritin Is Associated with Reduced Survival in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e45034.	2.5	72
123	Absence of the OPTN mutation in a patient with ALS and familial primary open angle glaucoma. Journal of the Neurological Sciences, 2011, 309, 16-17.	0.6	1
124	Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 557.e11-557.e13.	3.1	68
125	APOE Îµ4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. European Journal of Neurology, 2011, 18, 1046-1052.	3.3	17
126	Respiratory onset in an ALS family with L144F SOD1 mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 747-749.	1.9	6

#	Article	IF	Citations
127	Progression in ALS is not linear but is curvilinear. Journal of Neurology, 2010, 257, 1713-1717.	3.6	124
128	CADASIL and ALS: A link?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 399-401.	2.1	6
129	SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. Journal of Medical Genetics, 2010, 47, 554-560.	3.2	266
130	Primary lateral sclerosis may occur within familial amyotrophic lateral sclerosis pedigrees. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 154-156.	2.1	18
131	Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9004-9009.	7.1	177
132	Association study of the ubiquitin conjugating enzyme gene UBE2H in sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 432-435.	2.1	9
133	The importance of theSMNgenes in the genetics of sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 436-440.	2.1	30
134	Management of Amyotrophic Lateral Sclerosis. Drugs, 2008, 68, 1037-1048.	10.9	37
135	Genetica della sclerosi laterale amiotrofica. EMC - Neurologia, 2008, 8, 1-8.	0.0	0
136	Mutations of the ANG Gene in French Patients With Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 1333.	4.5	52
137	Breast cancer and motor neuron disease: Clinical study of seven cases. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 288-291.	2.1	12
138	SMN1 gene, but not SMN2 , is a risk factor for sporadic ALS. Neurology, 2006, 67, 1147-1150.	1.1	80
139	Improvement of a CIDP associated with hepatitis C virus infection using antiviral therapy. Neurology, 2004, 63, 179-180.	1.1	32
140	N19S, a new SOD1 mutation in sporadic amyotrophic lateral sclerosis: No evidence for disease causation. Annals of Neurology, 2003, 53, 815-818.	5.3	23
141	SMN1 gene study in three families in which ALS and spinal muscular atrophy co-exist. Neurology, 2002, 59, 1464-1466.	1.1	14
142	Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Annals of Neurology, 2002, 51, 243-246.	5.3	111